C F Craddock

Summary

Affiliation: University Hospital Birmingham
Country: UK

Publications

  1. ncbi request reprint Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia
    Sudhir Tauro
    Department of Hematology, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom
    J Clin Oncol 23:9387-93. 2005
  2. pmc Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples
    Victoria J Spanswick
    CR UK Drug DNA Interactions Research Group, UCL Cancer Institute, London, WC1E 6BT, UK
    BMC Cancer 12:436. 2012
  3. doi request reprint Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
    C Craddock
    Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK
    Leukemia 27:1028-36. 2013
  4. ncbi request reprint Biology and management of relapsed acute myeloid leukaemia
    Charles Craddock
    Leukaemia Unit, Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK
    Br J Haematol 129:18-34. 2005
  5. doi request reprint Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML
    C F Craddock
    Centre for Clinical Haematology, University Hospital Birmingham NHS Trust, Birmingham, UK
    Bone Marrow Transplant 41:415-23. 2008
  6. ncbi request reprint Molecularly targeted therapy in myeloid leukaemias
    Charles Craddock
    Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham
    Clin Med 7:632-5. 2007
  7. pmc Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia
    Charles Craddock
    Centre for Clinical Haematology, Main Drive, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK
    Haematologica 95:989-95. 2010
  8. doi request reprint Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia
    C Craddock
    Centre for Clinical Haematology, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK
    Leukemia 25:808-13. 2011
  9. ncbi request reprint Realising the potential of targeted therapies in oncology
    C Craddock
    Department of Haematology, University Hospital, Birmingham B15 2TH, UK
    Lancet 360:424-5. 2002
  10. doi request reprint Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex
    Charles Craddock
    Queen Elizabeth Hospital, Birmingham, UK
    Expert Opin Drug Saf 9:139-47. 2010

Collaborators

Detail Information

Publications43

  1. ncbi request reprint Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia
    Sudhir Tauro
    Department of Hematology, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom
    J Clin Oncol 23:9387-93. 2005
    ....
  2. pmc Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples
    Victoria J Spanswick
    CR UK Drug DNA Interactions Research Group, UCL Cancer Institute, London, WC1E 6BT, UK
    BMC Cancer 12:436. 2012
    ..Conversely, enhanced repair can result in clinical acquired resistance following chemotherapy. The repair of ICLs is complex but it is assumed that the 'unhooking' step is common to all ICLs...
  3. doi request reprint Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
    C Craddock
    Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK
    Leukemia 27:1028-36. 2013
    ..LSC quantitation provides a novel biomarker of disease response and relapse in patients with AML treated with epigenetic therapies. New drugs that target this cellular population in vivo are required...
  4. ncbi request reprint Biology and management of relapsed acute myeloid leukaemia
    Charles Craddock
    Leukaemia Unit, Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK
    Br J Haematol 129:18-34. 2005
    ....
  5. doi request reprint Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML
    C F Craddock
    Centre for Clinical Haematology, University Hospital Birmingham NHS Trust, Birmingham, UK
    Bone Marrow Transplant 41:415-23. 2008
    ....
  6. ncbi request reprint Molecularly targeted therapy in myeloid leukaemias
    Charles Craddock
    Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham
    Clin Med 7:632-5. 2007
  7. pmc Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia
    Charles Craddock
    Centre for Clinical Haematology, Main Drive, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK
    Haematologica 95:989-95. 2010
    ..Although T-cell depletion is increasingly used to reduce the risk of graft-versus-host disease its impact on the graft-versus-leukemia effect and long-term outcome post-transplant is unknown...
  8. doi request reprint Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia
    C Craddock
    Centre for Clinical Haematology, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK
    Leukemia 25:808-13. 2011
    ....
  9. ncbi request reprint Realising the potential of targeted therapies in oncology
    C Craddock
    Department of Haematology, University Hospital, Birmingham B15 2TH, UK
    Lancet 360:424-5. 2002
  10. doi request reprint Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex
    Charles Craddock
    Queen Elizabeth Hospital, Birmingham, UK
    Expert Opin Drug Saf 9:139-47. 2010
    ....
  11. ncbi request reprint Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion
    R J Lush
    Department of Haematology, Nottingham City Hospital, UK
    Cytotherapy 3:203-10. 2001
    ....
  12. doi request reprint Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study
    P G Medd
    Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK
    Bone Marrow Transplant 48:982-7. 2013
    ..035 and HR = 0.52, P = 0.025, respectively). Long-term ALL-free survival is achievable following fludarabine-based RIC allo-SCT. The association between GVHD and decreased RI suggests the presence of a GVL effect...
  13. doi request reprint Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant
    B E Shaw
    Department of Haematology, Royal Marsden Hospital, Institute of Cancer Research, London, UK
    Bone Marrow Transplant 42:783-9. 2008
    ..014). These data support our hypothesis that the second RIC allograft results in a lower TRM than using MA. A proportion of patients achieved a sustained remission even when relapsing after a previous MA transplant...
  14. ncbi request reprint Optimizing the use of cyclosporin in allogeneic stem cell transplantation
    N Duncan
    Pharmacy Department, Queen Elizabeth Hospital, University Hospital Birmingham NHS Trust, Birmingham, UK
    Bone Marrow Transplant 38:169-74. 2006
    ....
  15. doi request reprint Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML
    R K Malladi
    Department of Haematology, John Radcliffe Hospital, Oxford, UK
    Bone Marrow Transplant 43:709-15. 2009
    ..02). In conclusion, alemtuzumab has a beneficial effect by reducing chronic GVHD without affecting overall survival. Further studies are warranted before alemtuzumab can be recommended as standard in RIC allografts for AML...
  16. ncbi request reprint High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience
    E Olavarria
    Department of Haematology, Hammersmith Hospital, ICSM, London, UK
    Br J Haematol 108:769-77. 2000
    ..High-dose busulphan alone appears sufficient to provide adequate cytoreduction and immunosuppression in second allogeneic transplants and is also effective as cytoreduction before autologous SCT in patients with CML...
  17. ncbi request reprint Short Report: Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen
    C Craddock
    Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK
    Br J Haematol 111:797-800. 2000
    ..All but one patient demonstrated durable engraftment and no patient receiving a TCD product developed severe GVHD. Thus, TCD may play a role in GvHD prophylaxis using such regimens...
  18. ncbi request reprint Increased acute GvHD and higher transplant-related mortality in non-caucasians undergoing standard sibling allogeneic stem cell transplantation
    M Karanth
    Bone Marrow Transplant Unit, University Hospital Birmingham NHS Trust, Birmingham, UK
    Bone Marrow Transplant 37:419-23. 2006
    ....
  19. ncbi request reprint Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia
    S Tauro
    Bone Marrow Transplant Unit, University Hospital, Birmingham, UK
    Bone Marrow Transplant 32:273-8. 2003
    ..7 months, P=0.0002). Thus Ara-amsa can be used effectively to salvage HR-leukaemia, enabling further consolidation with SCT...
  20. doi request reprint Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT
    B Pourgheysari
    CRUK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, UK
    Bone Marrow Transplant 43:853-61. 2009
    ..Measurement of the magnitude of the CMV-specific CD4+ immune response is useful in managing viral reactivation following HSCT...
  21. ncbi request reprint Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse
    T I Mughal
    Department of Haematology, Hammersmith Hospital, Imperial College School of Medicine, London, UK
    Br J Haematol 115:569-74. 2001
    ..We conclude that molecular studies during the first 5 years post transplant can help to predict long-term leukaemia-free survival and, possibly, cure of CML...
  22. ncbi request reprint The use of a national transplant registry to benchmark transplant outcome for patients undergoing autologous and allogeneic stem cell transplantation in the United Kingdom and Ireland
    N H Russell
    Department of Haematology, Nottingham City Hospital, London, UK
    Br J Haematol 124:499-503. 2004
    ..8% (EBMT) and 70.8% (BSBMT). TRM was not statistically different in either disease. This study demonstrates the potential for using national registries to benchmark transplant outcome against the EBMT registry...
  23. ncbi request reprint Haemopoietic stem-cell transplantation: recent progress and future promise
    C Craddock
    Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK
    Lancet Oncol 1:227-34. 2000
    ....
  24. ncbi request reprint Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation
    K Raj
    Department of Haematology, Guy s, King s and St Thomas School of Medicine, London, UK
    Bone Marrow Transplant 35:299-301. 2005
    ..We conclude that Rituximab can be a valuable agent in the management of autoimmune cytopenias occurring after allogeneic SCT and that autoimmune cytopenias may be a hitherto unrecognised complication of RIC regimens...
  25. ncbi request reprint Stem cell transplantation for chronic myeloid leukaemia: the role of infused marrow cell dose
    C Pocock
    Department of Haematology, Hammersmith Hospital, Imperial College School of Medicine, London, UK
    Hematol J 2:265-72. 2001
    ..The data support the recommendation that bone marrow harvest teams should aim to collect the highest possible number of nucleated cells for recipients of unrelated donor transplants...
  26. ncbi request reprint High-hyperdiploidy in Philadelphia positive adult acute lymphoblastic leukaemia: case-series and review of literature
    S Tauro
    Bone Marrow Transplant Unit, University Hospital Birmingham NHS Trust, UK
    Bone Marrow Transplant 31:763-6. 2003
    ..We have discussed these results in the context of recent studies on the significance of high-hyperdiploidy in Ph(+) adult ALL...
  27. pmc High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels
    E J Kanfer
    Department of Haematology, Imperial College School of Medicine at Charing Cross Hospital, Hammersmith Hospitals NHS Trust, London, UK
    Br J Cancer 78:928-32. 1998
    ..An etoposide dose of 1.6 g m(-2) appears to be as effective as higher doses but less toxic...
  28. ncbi request reprint Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions
    K Cwynarski
    Department of Haematology, Hammersmith Hospital, ICSM, London, UK
    Bone Marrow Transplant 28:581-6. 2001
    ..We conclude that in the context of leukaemic relapse, DLI is an effective therapy for IHA following allografts involving TCD...
  29. ncbi request reprint CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation
    Karen P Piper
    Cancer Research United Kingdom Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom
    Blood 110:3827-32. 2007
    ..These findings indicate that CXCL10 plays a central role in the pathogenesis of skin aGVHD by the recruitment of CXCR3(+) T cells to the sites of inflammation...
  30. ncbi request reprint Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study
    Andrew D Chantry
    Academic Unit of Bone Biology, University of Sheffield Medical School, Sheffield, UK
    Biol Blood Marrow Transplant 12:1310-7. 2006
    ..TBI conditioning did not confer an advantage. Randomized studies against unrelated donor transplantation are warranted...
  31. ncbi request reprint Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen
    Ronjon Chakraverty
    Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, United Kingdom
    Blood 99:1071-8. 2002
    ..In summary, a nonmyeloablative regimen incorporating in vivo CAMPATH-1H is effective in promoting durable engraftment in most patients and in reducing the risk of severe GVHD following matched unrelated donor transplantation...
  32. ncbi request reprint Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation
    Eduardo Olavarria
    Haematology Department, Hammersmith Hospital, London, England
    Blood 99:3861-2. 2002
    ..This case demonstrates that imatinib mesylate can be highly effective in the management of patients who have relapses after allograft for CML...
  33. ncbi request reprint High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
    Suparno Chakrabarti
    Department of Haematology, Birmingham Heartlands Hospital, University of Birmingham, Birmingham, United Kingdom
    Blood 99:4357-63. 2002
    ..The use of Campath-1H appeared to be associated with a low incidence of GVHD but a high incidence of CMV infections and prolonged immune paresis...
  34. ncbi request reprint Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies
    Katharine Branson
    CR UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom
    J Clin Oncol 20:4022-31. 2002
    ..The aim of the current study was to evaluate the safety and efficacy of sibling, HLA-matched, nonmyeloablative allogeneic SCT with donor lymphocyte infusion (DLI) in patients with lymphoid malignancy after failure of autologous SCT...
  35. ncbi request reprint Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders
    Jose A Perez-Simon
    Department of Hematology, Hospital Universitairo de Salamanca, Paseo de San Vicente s n, 37007 Salamanca, Spain
    Blood 100:3121-7. 2002
    ..Patients receiving alemtuzumab often required DLIs to achieve similar tumor control but the incidence of GVHD was not significantly increased after DLI...
  36. ncbi request reprint BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients
    Rowena D Faulkner
    Academic Haematology, Clinical Sciences Bldg, City Hospital, Nottingham, NG5 1PB United Kingdom
    Blood 103:428-34. 2004
    ....
  37. ncbi request reprint Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells
    Fiona J Clark
    Department of Hematology, Institute of Cancer Studies, University of Birmingham, Edgbaston, United Kingdom
    Blood 103:2410-6. 2004
    ..These results indicate that chronic graft-versus-host injury does not occur as a result of Treg cell deficiency...
  38. ncbi request reprint Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma
    Emma Morris
    Department of Haematology, Royal Free and University College Hospitals Medical School, 98 Chenies Mews, London WC1E 6HX, United Kingdom
    Blood 104:3865-71. 2004
    ..Patients who experienced relapses of LG-NHL and chronic lymphocytic leukemia (CLL) achieved excellent PFS with extremely low TRM and GVHD, even when matched related donors were unavailable...
  39. ncbi request reprint Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation
    Karl S Peggs
    Department of Haematology, Royal Free and University College London, UK
    Lancet 365:1934-41. 2005
    ..Therefore, we aimed to assess the graft-versus-tumour effect of reduced-intensity allogeneic transplantation...
  40. pmc Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers
    Mark Cobbold
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham B15 2TT, England, UK
    J Exp Med 202:379-86. 2005
    ..This novel approach to adoptive transfer has considerable potential for antigen-specific T cell therapy...
  41. ncbi request reprint Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation
    Mark Cook
    Department of Haematology, University Hospital Birmingham NHS Trust, Edgbaston, Birmingham, United Kingdom
    Blood 107:1230-2. 2006
    ..This observation indicates that activating KIRs play an important role in the cellular control of CMV reactivation...
  42. ncbi request reprint Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease
    Fiona J Clark
    Department of Haematology, Institute of Cancer Studies, University of Birmingham, Birmingham, UK
    Transplantation 75:221-5. 2003
    ..The role of antigen presentation in the development of chronic graft-versus host disease (cGVHD) is unknown...
  43. ncbi request reprint Survival after bone-marrow transplantation
    Kate Cwynarski
    Lancet 359:887-8. 2002